EUVIMEDEUVIMED entdecken
Fallbericht

Niraparib as a therapeutic agent for the treatment of ovarian cancer meningeal dissemination with BRCA1 mutation

Takashi Nei, Satoshi Tamauchi iD, Yoshiki Ikeda iD, Nobuhisa Yoshikawa iD, Kaoru Niimi iD, Hiroaki Kajiyama iD

Journal of Obstetrics and Gynaecology Research · 2023

DOI: 10.1111/jog.15663 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2023. Verfasst von Takashi Nei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: Ovarian Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study analyzed a 63‐year‐old woman with hereditary BRCA1 mutation. She underwent interval debulking surgery after neoadjuvant chemotherapy for high‐grade serous ovarian carcinoma (HGSOC). After 2 years of postoperative chemotherapy, she developed headache and dizziness, and a suspected metastatic cerebellar mass in left ovary was detected. Pathological analysis of the mass revealed HGSOC, which was removed surgically. Eight months and another 6 months after the surgery, local recurrence was noted; hence, she underwent CyberKnife treatment. After 3 months, cervical spinal cord metastasis was found, evidenced by left shoulder pain. Moreover, meningeal dissemination was present around the cauda equina. Chemotherapy treatment, including bevacizumab, was ineffective and increased lesions were observed. After CyberKnife treatment for the cervical spinal cord metastasis, niraparib was initiated for the meningeal dissemination. The cerebellar lesions and meningeal dissemination improved within 8 months of niraparib treatment. Although meningeal dissemination is challenging to treat, niraparib may be useful in BRCA ‐mutated HGSOC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsHumansFemaleMiddle AgedCarcinoma, Ovarian EpithelialIndazolesGerm-Line MutationMutationBRCA1 ProteinPiperidines

Stichwörter der Autor:innen

mutationneoadjuvant therapyniraparibovarian neoplasms

Substanzen

IndazolesBRCA1 ProteinniraparibPiperidinesBRCA1 protein, human

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

ORCID-Profile: Satoshi Tamauchi, Yoshiki Ikeda, Nobuhisa Yoshikawa, Kaoru Niimi, Hiroaki Kajiyama

Zitieren

APA

Nei, T., Tamauchi, S., Ikeda, Y., Yoshikawa, N., Niimi, K., & Kajiyama, H. (2023). Niraparib as a therapeutic agent for the treatment of ovarian cancer meningeal dissemination with BRCA1 mutation. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.15663

Vancouver

Nei T, Tamauchi S, Ikeda Y, Yoshikawa N, Niimi K, Kajiyama H. Niraparib as a therapeutic agent for the treatment of ovarian cancer meningeal dissemination with BRCA1 mutation. Journal of Obstetrics and Gynaecology Research. 2023. doi:10.1111/jog.15663

BibTeX
@article{Nei2023,
  author = {Nei, Takashi and Tamauchi, Satoshi and Ikeda, Yoshiki and Yoshikawa, Nobuhisa and Niimi, Kaoru and Kajiyama, Hiroaki},
  title = {Niraparib as a therapeutic agent for the treatment of ovarian cancer meningeal dissemination with BRCA1 mutation},
  journal = {Journal of Obstetrics and Gynaecology Research},
  year = {2023},
  doi = {10.1111/jog.15663}
}
Kostenlos starten →